专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07132506B2 Peptide having osteogenetic activity and osteogenetic accelerator containing the same 有权
标题翻译：具有成骨活性的肽和含有其的成骨加速剂
公开(公告)号：US07132506B2
公开(公告)日：2006-11-07
申请号：US10233284
申请日：2002-08-30
申请人： Yoshihiko Nishimura , Yoshihisa Suzuki , Masao Tanihara
发明人： Yoshihiko Nishimura , Yoshihisa Suzuki , Masao Tanihara
IPC分类号： A61K38/07 , A61K38/08 , A61K38/10 , A61K38/16 , C07K7/04
CPC分类号： C07K14/51 , A61K38/00
摘要： A peptide has at least an amino acid sequence represented by SEQ ID NO:1 and it has an osteogenetic activity.
摘要翻译：肽至少具有SEQ ID NO：1所示的氨基酸序列，并具有成骨活性。

2. 发明授权

US5980883A Polymer gel for medical use 失效
标题翻译：用于医疗用途的聚合物凝胶
公开(公告)号：US5980883A
公开(公告)日：1999-11-09
申请号：US932096
申请日：1997-09-17
申请人： Masao Tanihara , Yoshimi Kakimaru
发明人： Masao Tanihara , Yoshimi Kakimaru
IPC分类号： A61K47/48 , A61K31/765 , A61K31/785
CPC分类号： A61K47/48784 , A61K47/48238
摘要： Provided is a medical material useful for wound dressings or a drug delivery system, which material is safe and has high healing effects, more specifically, which is free from cytotoxicity or other side effects caused by a drug and permits the selective healing of the diseased site in a small dosage without damaging the sites other than the diseased site.The medical material so provided is a polymer gel having a sequence represented by the formula: A-Sp1-E-Sp2-G wherein A represents a water-swelling polymer gel, Sp1 represents the first spacer, E represents a cleavable group with the main chain to be cleaved via an enzymatic reaction, Sp2 represents the second spacer and G represents a drug. When the polymer gel is used, the cleavable group (E) is cleaved according to an amount of an enzyme existing at the diseased site to release the drug in accordance with the amount of the enzyme.
摘要翻译：提供了一种用于伤口敷料或药物递送系统的医疗材料，该材料是安全的并且具有高愈合效果，更具体地说，其不受药物引起的细胞毒性或其它副作用，并允许病变部位的选择性愈合在不损害除病变部位之外的部位的小剂量。如此提供的医疗材料是具有由下式表示的序列的聚合物凝胶：A-Sp1-E-Sp2-G其中A表示水溶胀性聚合物凝胶，Sp1表示第一间隔物，E表示主要的可裂解基团链通过酶反应裂解，Sp2表示第二间隔物，G表示药物。当使用聚合物凝胶时，可切割基团（E）根据存在于患病部位的酶的量根据酶的量来释放药物而被切割。

3. 发明授权

US5770229A Medical polymer gel 失效
标题翻译：医用聚合物凝胶
公开(公告)号：US5770229A
公开(公告)日：1998-06-23
申请号：US826097
申请日：1997-03-24
申请人： Masao Tanihara , Hisao Kinoshita
发明人： Masao Tanihara , Hisao Kinoshita
IPC分类号： A61K47/48 , A61L15/44 , A61L15/60 , A61L26/00 , A61L27/54 , A61L31/14 , A61L31/16 , A61K9/10
CPC分类号： A61L31/145 , A61K47/48784 , A61L15/44 , A61L15/60 , A61L26/0066 , A61L26/008 , A61L27/54 , A61L31/16 , A61L2300/00 , A61L2300/602 , Y10S514/944
摘要： A medical polymer gel produced by immobilizing a drug onto a water swelling polymer gel through a cleavable group with the main chain to be cleaved via an enzymatic reaction and a spacer, and a water swelling polymer gel produced by covalently crosslinking a polysaccharide having a carboxyl group within the molecule with a diaminoalkane derivative as the crosslinking reagent. Because the medical polymer gel exerts a drug releasing property depending on the level of an enzyme, the gel can release a therapeutically effective dose of a drug only at a focal lesion generating the enzyme. The medical polymer gel is useful as the structural component of wound dressings, adhesives for biological tissues, adhesion preventing agents, bone reinforcing agents, and drug releasing base materials. Wound dressings comprising the structural material of the water swelling polymer gel of the present invention, can be applied to a patient with wound, burn, and decubitus to promote the healing of the wounds of the patient.
摘要翻译：一种医用聚合物凝胶，其通过可裂解的基团将药物固定在水溶胀性聚合物凝胶上，通过酶反应和间隔物将待裂解的主链和通过共价交联具有羧基的多糖而产生的水溶性聚合物凝胶在分子内具有二氨基烷烃衍生物作为交联剂。由于医用聚合物凝胶根据酶的水平发挥药物释放性质，所以凝胶只能在产生酶的局灶性病变处释放治疗有效剂量的药物。医用聚合物凝胶可用作伤口敷料的结构组分，用于生物组织的粘合剂，防粘连剂，骨增强剂和药物释放基材。包含本发明的水溶性聚合物凝胶的结构材料的伤口敷料可以应用于患有伤口，烧伤和褥疮的患者，以促进患者的伤口的愈合。

4. 发明申请

US20080009604A1 Novel polypeptide and process for producing the same 有权
标题翻译：新型多肽及其制备方法
公开(公告)号：US20080009604A1
公开(公告)日：2008-01-10
申请号：US11878724
申请日：2007-07-26
申请人： Masao Tanihara , Chikara Otsuki , Hiroshi Mikami , Hisao Kinoshita
发明人： Masao Tanihara , Chikara Otsuki , Hiroshi Mikami , Hisao Kinoshita
IPC分类号： C07K1/02
CPC分类号： C07K7/08 , C07K14/001 , C07K14/78
摘要： A peptide component (A) represented by the following formula (1a) with a peptide component (B) represented by the following formula (2a) and a compound (C) represented by the following formula (3a), as an optional component are subjected to a condensation reaction in the presence of a dehydrating and condensing agent and a condensing auxiliary; provided that in the case where “X” represents HOOC—(CH2)m—CO— in the formula (1a) and/or (2a), the reaction is conducted with the compound (C). The ratio of the peptide component (A) relative to the peptide component (B) is 100/0 to 30/70 (mol %), and the ratio of the compound (C) relative to the total molar amount of the peptide component (A) and/or the peptide component (B). X-(Pro-Y-Gly)n-OH (1a), X—(Z)r—OH (2a), H2N—R—NH2 (3a) Wherein “X” represents H or the group HOOC—(CH2)m—CO— (“m”=1 to 18), “Y” represents Pro or Hyp, “n”=1 to 20, “Z” represents a peptide chain comprising 1 to 10 amino acid residue(s), “r”=1 to 20, and “R” represents a linear or branched alkylene group. The present invention provides a collagenous polypeptide which is free from a risk of an infection by a pathogenic organism (or a causative factor) or an undesirable side effect, and which has a high safety.
摘要翻译：将由下式（1a）表示的肽成分（B）表示的肽成分（A）和下述式（3a）表示的化合物（C））作为任意成分进行在脱水缩合剂和冷凝助剂的存在下进行缩合反应; 条件是在“X”表示式（1a）和/或（2a）中的HOOC-（CH 2）m - CO-）的情况下，反应是与化合物（C）进行反应。肽成分（A）相对于肽成分（B）的比例为100/0〜30/70（摩尔％），化合物（C）相对于肽成分的总摩尔量 A）和/或肽组分（B）。 X-（Pro-Y-Gly）n -OH（1a），X-（Z）-OH（2a），H 2 其中，“X”表示H或HOOC-（CH 2）m -CO-（“ m“= 1〜18），”Y“表示Pro或Hyp，”n“= 1〜20，”Z“表示包含1〜10个氨基酸残基，”r“= 1〜20， “R”表示直链或支链亚烷基。本发明提供一种胶原多肽，其不具有致病生物（或致病因子）感染的风险或不期望的副作用，并且具有高安全性。

5. 发明申请

US20070224251A1 Hemostatic material 审中-公开
标题翻译：止血材料
公开(公告)号：US20070224251A1
公开(公告)日：2007-09-27
申请号：US11385750
申请日：2006-03-22
申请人： Masao Tanihara , Hisao Kinoshita , Takayuki Imamura , Chikateru Nozaki
发明人： Masao Tanihara , Hisao Kinoshita , Takayuki Imamura , Chikateru Nozaki
IPC分类号： A61K38/48 , A61L15/00
CPC分类号： A61K38/4833 , A61L15/225 , A61L15/32 , A61L24/043 , A61L24/10 , A61L2400/04
摘要： The present invention provides a hemostatic material which is excellent in hemostatic property, biodegradability and bioabsorbability, uniformity and stability of the quality, as well as reduces a risk of contamination with a pathogenic organism derived from an animal. The hemostatic material comprises a thrombin and a synthetic polypeptide capable of forming a triple helical structure. The polypeptide may show a peak of the molecular weight in the range from 5×104 to 100×104 in the molecular weight distribution. The polypeptide may contain at least a peptide unit represented by the formula: -Pro-X-Gly- (in the formula, X represents Pro or Hyp). The thrombin may be a recombinant. In the hemostatic material, the proportion of the thrombin may be about 0.1 to 500 units (U) relative to 1 mg of the polypeptide. The hemostatic material may further comprise a binder component having biodegradability and bioabsorbability. The hemostatic material may be formed on a substrate.
摘要翻译：本发明提供止血性，生物降解性和生物吸收性，质量的均匀性和稳定性优异的止血材料，并且降低了来自动物的病原体的污染的风险。止血材料包含能够形成三重螺旋结构的凝血酶和合成多肽。多肽可以在分子量分布中显示分子量在5×10 4至100×10 4范围内的峰。多肽可以至少含有由下式表示的肽单元：-Pro-X-Gly-（在该式中，X表示Pro或Hyp）。凝血酶可以是重组体。在止血材料中，相对于1mg多肽，凝血酶的比例可以为约0.1至500单位（U）。止血材料还可以包含具有生物降解性和生物吸收性的粘合剂组分。止血材料可以形成在基底上。

6. 发明授权

US06617307B1 Peptide and osteogenetic accelerator 有权
标题翻译：肽和成骨加速器
公开(公告)号：US06617307B1
公开(公告)日：2003-09-09
申请号：US09439779
申请日：1999-11-12
申请人： Yoshihiko Nishimura , Yoshihisa Suzuki , Masao Tanihara
发明人： Yoshihiko Nishimura , Yoshihisa Suzuki , Masao Tanihara
IPC分类号： A61K3803
CPC分类号： C07K14/51 , A61K38/00
摘要： A peptide has any one of the sequences SEQ ID NO.1 to SEQ ID NO.8, or has a sequence derived from any one of the sequences SEQ ID NO.1 to SEQ ID NO.8 by substitution, deletion or addition of one or several amino acids therein and having an osteogenetic activity.
摘要翻译：肽具有SEQ ID NO.1至SEQ ID NO.8中的任一个，或具有通过取代，缺失或添加一个序列SEQ ID NO.1至SEQ ID NO.8中任一个序列的序列或其中的几个氨基酸并具有成骨活性。

7. 发明授权

US5658592A Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane 失效
标题翻译：羧基多糖和二氨基烷烃的医用交联聚合物凝胶
公开(公告)号：US5658592A
公开(公告)日：1997-08-19
申请号：US571976
申请日：1996-01-16
申请人： Masao Tanihara , Hisao Kinoshita
发明人： Masao Tanihara , Hisao Kinoshita
IPC分类号： A61K47/48 , A61L15/44 , A61L15/60 , A61L26/00 , A61L27/54 , A61L31/14 , A61L31/16 , A61K9/10
CPC分类号： A61L31/145 , A61K47/48784 , A61L15/44 , A61L15/60 , A61L26/0066 , A61L26/008 , A61L27/54 , A61L31/16 , A61L2300/00 , A61L2300/602 , Y10S514/944
摘要： A water swelling polymer gel produced by covalently crosslinking a polysaccharide having a carboxyl group within the molecule with a diaminoalkane derivative as the crosslinking reagent. The medical polymer gel is useful as the structural component of wound dressings, adhesives for biological tissues, adhesion preventing agents, bone reinforcing agents, and drug releasing base materials. Wound dressings comprising the structural material of the water swelling polymer gel of the present invention, can be applied to a patient with wound, burn, and decubitus to promote the healing of the wounds of the patient.
摘要翻译： PCT No.PCT / JP95 / 00873 Sec。 371日期1996年1月16日 102（e）日期1996年1月16日PCT提交1995年5月8日PCT公布。 WO95 / 31223 PCT出版物日期：1995年11月23日通过在分子内共价交联具有羧基的多糖与二氨基烷烃衍生物作为交联剂而制得的水溶胀性聚合物凝胶。医用聚合物凝胶可用作伤口敷料的结构组分，用于生物组织的粘合剂，防粘连剂，骨增强剂和药物释放基材。包含本发明的水溶性聚合物凝胶的结构材料的伤口敷料可以应用于患有伤口，烧伤和褥疮的患者，以促进患者的伤口的愈合。

8. 发明授权

US5624900A Peptide or its salts 失效
标题翻译：肽或其盐
公开(公告)号：US5624900A
公开(公告)日：1997-04-29
申请号：US239854
申请日：1994-05-09
申请人： Tatsuo Suda , Etsuko Abe , Masao Tanihara , Chie Fujiwara
发明人： Tatsuo Suda , Etsuko Abe , Masao Tanihara , Chie Fujiwara
IPC分类号： A61K38/00 , C07K14/715 , C07K7/06 , C07K7/08
CPC分类号： C07K14/7155 , A61K38/00
摘要： Peptides having high binding activity for human interleukin-1 and represented by the following formulaH-X.sup.1 -Cys-A-B-A-B-A-Ser-X.sup.2 -Ywherein each A represents an amino acid residue selected from the group consisting of Val, Leu, Ile and Nle, independent of any other selection for A; B represents an amino acid residue selected from the group consisting of Arg, Lys, Gln, His and Ser, independent of any other selection for B; X.sup.1 and X.sup.2 each is a single bond or a peptide segment comprising 1-10 amino acid residues selected from Gly, Ala, Val, Arg, Asn, Ser, Phe, Pro, Leu, Glu, Asp, Lys, Thr, His, Tyr, Nle and Ile and Y represents a hydroxyl group or an amino group; and their salts.
摘要翻译：由人白细胞介素-1具有高结合活性且由下式H-X1-Cys-ABABA-Ser-X2-Y表示的肽，其中每个A代表选自Val，Leu，Ile和Nle的氨基酸残基，独立于A的任何其他选择; B代表选自Arg，Lys，Gln，His和Ser的氨基酸残基，与B的任何其它选择无关; X1和X2各自是单键或包含1-10个选自Gly，Ala，Val，Arg，Asn，Ser，Phe，Pro，Leu，Glu，Asp，Lys，Thr，His，Tyr的1-10个氨基酸残基的肽段，Nle和Ile，Y表示羟基或氨基; 和它们的盐。

9. 发明授权

US5132402A Adsorbent, method for production thereof, and method for use thereof 失效
标题翻译：吸附剂，其制造方法及其使用方法
公开(公告)号：US5132402A
公开(公告)日：1992-07-21
申请号：US265540
申请日：1988-11-01
申请人： Masao Tanihara , Kiichiro Oka , Hideaki Yamada , Akira Kobayashi , Toshihide Nakashima , Yoshiaki Omura , Koichi Takakura
发明人： Masao Tanihara , Kiichiro Oka , Hideaki Yamada , Akira Kobayashi , Toshihide Nakashima , Yoshiaki Omura , Koichi Takakura
IPC分类号： A61M1/36 , C07K14/705
CPC分类号： C07K14/705 , A61M1/3679
摘要： There is disclosed an adsorbent, comprising a carrier on which is immobilized a peptide possessing an ability to bind to the human antibody to the nicotinic acetylcholine receptor and represented by the formula:H--X--A--Y--Zwherein A stands for a peptide residue, one of X and Y stands for a single bond, an amino acid residue selected from the class consisting of Asp, Glu, Lys and a divalent group represented by the formula, ##STR1## (wherein n stands for an integer in the range of 1 to 17), or a peptide residue formed by peptide linkage of two to ten amino acid residues of at least one species selected from the class mentioned above and the other of X and Y stands for an amino acid residue selected from the class consisting of Asp, Glu, Lys and a divalent group represented by the formula, ##STR2## (wherein n stands for an integer in the range of 1 to 17), or a peptide residue formed by peptide linkage of two to ten amino acid residues of at least one species selected from the class mentioned above and Z stands for a hydroxyl group or an amino group. A method for the production of the adsorbent and a method for the use of the adsorbent are also disclosed.
摘要翻译：公开了一种吸附剂，其包含载体，其上固定有具有与烟碱乙酰胆碱受体的人抗体结合的能力并由下式表示的肽：HXAYZ其中A代表肽残基，X和Y之一对于单键，选自Asp，Glu，Lys和由下式表示的二价基团的氨基酸残基（其中n表示1至17的整数）或通过选自上述类别的至少一种的2至10个氨基酸残基和X和Y中的另一个的肽键形成的肽残基代表选自Asp，Glu，Lys和由下式表示的二价基团（其中n表示1〜17的整数），或由选自所述类别的至少一种的2〜10个氨基酸残基通过肽键形成的肽残基提到 Z代表羟基或氨基。还公开了制备吸附剂的方法和吸附剂的使用方法。

10. 发明授权

US4925787A Monoclonal anti-idiotypic antibody, method for production thereof, and hybridoma producing said antibody 失效
标题翻译：单克隆抗独特型抗体，其制备方法和产生所述抗体的杂交瘤
公开(公告)号：US4925787A
公开(公告)日：1990-05-15
申请号：US175303
申请日：1988-03-30
申请人： Masao Tanihara , Hideaki Yamada , Toshihide Nakashima , Yoshiaki Omura , Koichi Takakura
发明人： Masao Tanihara , Hideaki Yamada , Toshihide Nakashima , Yoshiaki Omura , Koichi Takakura
IPC分类号： C07K14/435 , A61K39/395 , A61P21/00 , A61P37/00 , C07K1/16 , C07K1/22 , C07K14/705 , C07K16/00 , C07K16/28 , C07K16/42 , C12N5/10 , C12N15/02 , C12P21/08 , C12R1/91 , G01N33/53 , G01N33/566 , G01N33/577 , G01N33/68 , G01N33/94
CPC分类号： C07K16/4258 , C07K16/286 , G01N33/686 , G01N33/9406 , Y10S530/808 , Y10S530/809 , Y10S530/813 , Y10S530/868
摘要： A monoclonal anti-idiotypic antibody specific to a human IgG.sub.1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor; a method for the production of the aforementioned monoclonal anti-idiotypic antibody by the steps of immunizing an animal with a human IgG.sub.1 type monoclonal antibody specific to nicotinic acetylcholine receptor, collecting antibody-producing cells from the animal, fusing the collected cells with neoplastic cells, selecting from the product of fusion a hybridoma capable of producing a monoclonal anti-idiotypic antibody specific to the human IgG.sub.1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor, propagating the selected hybridoma thereby giving rise to said monoclonal anti-idiotypic antibody, and collecting the produced monoclonal anti-idiotypic antibody; and use of the monoclonal anti-idiotypic antibody as a reagent and as an adsorbent.
摘要翻译：对具有烟碱型乙酰胆碱受体特异性的人IgG1型单克隆抗体特异性的单克隆抗独特型抗体; 通过以下步骤制备上述单克隆抗独特型抗体的方法：用对烟草乙酰胆碱受体特异性的人IgG1型单克隆抗体免疫动物，从动物收集抗体产生细胞，将收集的细胞与肿瘤细胞融合，从融合产物中选择能够产生对烟碱乙酰胆碱受体具有特异性的人IgG1型单克隆抗体特异性的单克隆抗独特型抗体的杂交瘤，繁殖所选择的杂交瘤，从而产生所述单克隆抗独特型抗体，并收集产生单克隆抗独特型抗体; 并使用单克隆抗独特型抗体作为试剂和吸附剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式